New Maryland FDA Complex to Pursue LEED Certification
May 12, 2008
The U.S. General Services Administration (GSA), in partnership with
the U.S. Department of Health and Human Services' Food and Drug
Administration (FDA), today dedicates building #51, the second
office building for the Center for Drug Evaluation and Research, at
the FDA's new headquarters facility in the White Oak Federal
Research Center, Silver Spring, Maryland.
The FDA complex, whose completion is contingent on congressional
funding, will be comprised of 14 interconnected buildings in a
campus setting. The new complex replaces 39 fragmented
facilities in the Washington DC metro area, co-locating
approximately 8,000 employees in award-winning new laboratories,
office buildings and support facilities. GSA is pursuing LEED
certification, promoting sustainable site development, water
savings, energy efficiency, materials selection, and indoor
environmental quality. The campus will encourage collaboration
among FDA's Center for Drug Evaluation and Research, Center for
Devices and Radiological Health, Center for Biologics Evaluation
and Research, Center for Veterinary Medicine, Office of Regulatory
Affairs, and Office of the Commissioner. The projected new
construction totals 2.33 million sq. ft. with four structured
parking garages.
The new building #51 is six stories, 300,000 sq. ft., and is
designed to house approximately 1,100 FDA employees and
contractors. The building was designed with an under floor air
distribution system giving occupants the ability to control their
room environments, raised flooring which allows flexibility of
space, and a narrow floor plate to allow as much natural light as
possible. Other spaces programmed for the building include shared
copy rooms, pantries, conference rooms, open team spaces and file
rooms. The core and shell design of building #51 incorporates
many elements of the earlier Center for Drug Evaluation and
Research office buildings #21 and #22 as well as the benefits of
lessons learned. The building facade design includes areas of
curtain wall, brick with large punched windows, solid brick and
limited areas of stone facing, as well as upgraded lobby finishes
and progressive collapse structural design.
ChetanNew Maryland FDA Complex to Pursue LEED Certification
May 12, 2008
The U.S. General Services Administration (GSA), in partnership with the U.S. Department of Health and Human Services' Food and Drug Administration (FDA), today dedicates building #51, the second office building for the Center for Drug Evaluation and Research, at the FDA's new headquarters facility in the White Oak Federal Research Center, Silver Spring, Maryland.
The FDA complex, whose completion is contingent on congressional funding, will be comprised of 14 interconnected buildings in a campus setting. The new complex replaces 39 fragmented facilities in the Washington DC metro area, co-locating approximately 8,000 employees in award-winning new laboratories, office buildings and support facilities. GSA is pursuing LEED certification, promoting sustainable site development, water savings, energy efficiency, materials selection, and indoor environmental quality. The campus will encourage collaboration among FDA's Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Veterinary Medicine, Office of Regulatory Affairs, and Office of the Commissioner. The projected new construction totals 2.33 million sq. ft. with four structured parking garages.
The new building #51 is six stories, 300,000 sq. ft., and is designed to house approximately 1,100 FDA employees and contractors. The building was designed with an under floor air distribution system giving occupants the ability to control their room environments, raised flooring which allows flexibility of space, and a narrow floor plate to allow as much natural light as possible. Other spaces programmed for the building include shared copy rooms, pantries, conference rooms, open team spaces and file rooms. The core and shell design of building #51 incorporates many elements of the earlier Center for Drug Evaluation and Research office buildings #21 and #22 as well as the benefits of lessons learned. The building facade design includes areas of curtain wall, brick with large punched windows, solid brick and limited areas of stone facing, as well as upgraded lobby finishes and progressive collapse structural design.
|